Taylor Morrison Home Corporation
NYSE:TMHCResidential Construction
+$0.33 today
- Market cap
- $6.67B
- Beta
- 1.48
- P/E (TTM)
- 10.3
- EPS (TTM)
- $7.00
Volume 2.52M
Average 2.42M
TMHC EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Taylor Morrison Home CorporationNYSE: TMHC
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA declines year over year
Q1 FY2026 EBITDA of $152.57M fell 48.5% year over year, behind the -22.4% change in trailing-twelve-month EBITDA. Sequentially, it fell 36.9% from the prior quarter. Over 3 fiscal years it compounded at -8.8% a year.
Context
- EBITDA amounted to 13.5% of revenue in FY2025, down 1.3 pp from a year earlier.
- EBITDA increased in 1 of the last 3 fiscal years.
What to watch
Whether EBITDA reaches the consensus estimate from 4 analysts of $905.78M (-17.4%) for the fiscal year ending Dec 2026, a slowdown from the -9.4% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $152.57M-36.9% QoQ
- Last fiscal yearDec 2025
- $1.1B-9.4% YoY
- LTMMar 2026
- $968.58M-22.4% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -48.5% | -26.9% | +21.5 pp |
| 1 year | -9.4% | -17.4% | -8.0 pp |
| 3-year CAGR | -8.8% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- 1.1B USD
- Year-over-year change
- -9.4%
- 4-year CAGR
- +5.2%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.1B | -9.4% |
| FY2024 | 2024-12-31 | 1.21B | +15.2% |
| FY2023 | 2023-12-31 | 1.05B | -27.2% |
| FY2022 | 2022-12-31 | 1.44B | +61.4% |
| FY2021 | 2021-12-31 | 894.79M | — |
EBITDA vs competitors
How TMHC compares with its peers on the latest reported figures
- TMHC's LTM Mar 2026 EBITDA of $968.58M is the 4th highest of the 11 companies compared; the peer median is $513.07M.
- Its year-over-year change of -22.4% is the 7th highest of 11, against a peer median of -6.2%.
- EBITDA amounts to 12.7% of revenue for TMHC, versus a peer median of 10.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Aug 2026 | $2.04B | +23.5% | -9.7% | 8.9% | |
| LTM Aug 2026 | $1.47B | -5.4% | -4.4% | 20.4% | |
| LTM Oct 2026 | $1.32B | -6.9% | +5.3% | 5.5% | |
| LTM Mar 2026 | $968.58M | -22.4% | -8.8% | 12.7% | |
| LTM Jul 2026 | $851.12M | +15.8% | +30.7% | 13.1% | |
| LTM Sep 2026 | $528.03M | -27.5% | -22.6% | 10.2% | |
| LTM Sep 2026 | $498.1M | -4.0% | +4.9% | 16.6% | |
| LTM Sep 2026 | $485M | -26.1% | -9.9% | 33.5% | |
| LTM Sep 2026 | $434.6M | -33.8% | -4.8% | 10.3% | |
| LTM Aug 2026 | $323.67M | -54.4% | -18.8% | 6.2% | |
| LTM Jun 2026 | $257.65M | +1.9% | -6.2% | 11.2% | |
| Peer median (excluding TMHC) | $513.07M | -6.2% | -5.5% | 10.8% | |
Competitors are the stored peer set for TMHC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 7.5B | 8.22B | 7.42B | 8.17B | 8.12B |
| Cost of Revenue | 5.94B | 6.11B | 5.62B | 6.15B | 6.25B |
| Gross Profit | 1.56B | 2.12B | 1.79B | 2.01B | 1.87B |
| Gross Margin | 20.8% | 25.7% | 24.2% | 24.7% | 23.0% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 668.34M | 643.21M | 698.71M | 770.5M | 734.99M |
| Operating Expenses | 668.34M | 643.21M | 698.71M | 770.5M | 734.99M |
| Depreciation & Amortization | 39.98M | 33.84M | 33.41M | 41.19M | 7.49M |
| EBITDA | 894.79M | 1.44B | 1.05B | 1.21B | 1.1B |
| EBITDA Margin | 11.9% | 17.6% | 14.2% | 14.8% | 13.5% |
| Operating Income | 888.18M | 1.47B | 1.1B | 1.24B | 1.14B |
| Operating Margin | 11.8% | 17.9% | 14.8% | 15.2% | 14.0% |
| Interest Income | 0 | 0 | 12.58M | 0 | 0 |
| Interest Expense | 3.79M | 17.67M | 0 | 13.32M | 47M |
| Other Income / Expenses | (25.08M) | (81.35M) | (78.32M) | (87.23M) | (93.17M) |
| Income Before Tax | 863.11M | 1.39B | 1.02B | 1.16B | 1.04B |
| Pre-Tax Margin | 11.5% | 16.9% | 13.7% | 14.2% | 12.8% |
| Income Tax Expense | 180.74M | 336.43M | 248.1M | 269.55M | 250.78M |
| Net Income | 663.03M | 1.05B | 768.93M | 883.31M | 782.5M |
| Net Margin | 8.8% | 12.8% | 10.4% | 10.8% | 9.6% |
| EPS (Basic) | 5.26 | 9.16 | 7.09 | 8.43 | 7.90 |
| EPS (Diluted) | 5.18 | 9.06 | 6.98 | 8.27 | 7.77 |
| Weighted Avg Shares | 126.08M | 114.98M | 108.42M | 104.13M | 99.07M |
| Weighted Avg Shares (Diluted) | 128.02M | 116.22M | 110.15M | 106.09M | 100.71M |
Taylor Morrison Home Corporation
NYSE:TMHC
Intrinsic Alpha fair value
Locked
Current Price
$72.45
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.